• Citer

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).

par Ponde, Noam;Bradbury, Ian;Lambertini, Matteo ;Ewer, Michael S;Campbell, Christine;Ameels, Helene;Zardavas, Dimitrios ;Di Cosimo, Serena;Baselga, José;Huober, Jens;Izquierdo, Miguel;Fumagalli, Debora ;Bozovic-Spasojevic, Ivana;Maetens, Marion M. ;Harbeck, Nadia;Pusztai, Lajos;Berghorn, Michael;Im, Young Hyuck;Borrego, Manuel Ruiz;Chen, Dar-Ren;Rodeheffer, Richard;Piccart-Gebhart, Martine ;Suter, Thomas;De Azambuja, Evandro
Référence Breast cancer research and treatment
Publication Publié, 2017-12

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Biomarkers of cardiac damages, such as troponin T (TnT) and the amino-terminal fragment of brain natriuretic peptide (NT-proBNP), may be useful as early predictors of cardiac dysfunction. The role of these biomarkers in patients receiving lapatinib and/or trastuzumab before anthracyclines is unknown. This study explores TnT and NT-proBNP as predictors of early cardiac toxicity in neoadjuvant breast cancer patients.